Risk of leukaemia, carcinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera: a prospective analysis of 682 cases. The "French Cooperative Group for the Study of Polycythaemias"

Leukemia & Lymphoma
Y NajeanM J Grange

Abstract

An analysis of the risk of progression towards leukemia, carcinoma and myelofibrosis was performed in 93 patients treated by 32P alone (PVSG protocols) since 1970-1979, 395 patients over the age of 65 years treated by 32P with or without maintenance therapy using hydroxyurea (French protocol) since 1980-1994, and 202 patients under the age of 65 treated by either hydroxyurea or pipobroman since 1980. The risk of leukemia, or myelodysplasia, or lymphoma in the 32P-treated patients was 10% at the 10th year, but increase after that time to reach a value of about 30% at the 20th year, in the surviving case. This risk was not dose-related. Despite a marked reduction of the cumulative 32P dose in the patients maintained by hydroxyurea, the actuarial risk was 19% at the 10th year. In the patients treated exclusively by non radio-mimetic agents (hydroxyurea or pipobroman) a risk of 10% at the 10th year was observed. The risk of carcinoma (excluding skin cancers) was about 15% at the 10th year in the 32P-treated cases, a value similar to that generally reported by the French statistics. There was no prevalence of digestive carcinomas. In contrast, the patients receiving 32P and hydroxyurea as maintenance had an excess risk: 29% at the 1...Continue Reading

References

Nov 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A B BensonK Anderson
May 1, 1990·American Journal of Hematology·S NandR I Fisher
Oct 1, 1988·European Journal of Haematology·E Löfvenberg, A Wahlin
Nov 1, 1987·British Journal of Haematology·Y NajeanJ D Rain
Feb 15, 1986·Cancer·R SharonY Ben-Arieh
Jul 1, 1974·Archives of Internal Medicine·M N Silverstein
Apr 1, 1969·Meditsinskaia radiologiia·N K GorbadeĭV I Lapchenkov
Jun 1, 1984·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E BrusamolinoC Bernasconi
Jan 1, 1984·British Journal of Haematology·Y NajeanC Dresch
Apr 1, 1984·Cancer Genetics and Cytogenetics·R BergerY Najean
Oct 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R LowskyH Messner
Jan 1, 1994·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J S Tobias, J Houghton
Jan 1, 1994·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C J Williams, M Zwitter
Jul 1, 1994·British Journal of Cancer·M OlschewskiD G Altman
Aug 1, 1994·British Journal of Cancer·C A Stiller
Dec 2, 1993·International Journal of Cancer. Journal International Du Cancer·P PisaniJ Ferlay
Jun 19, 1993·International Journal of Cancer. Journal International Du Cancer·D M ParkinJ Ferlay

❮ Previous
Next ❯

Citations

Jun 1, 2006·Current Hematologic Malignancy Reports·David Dingli, Ayalew Tefferi
Nov 3, 2001·The American Journal of Medicine·D Mintzer, A Bagg
Mar 9, 2012·Therapeutics and Clinical Risk Management·Alen OstojicSrdan Verstovsek
Apr 22, 2008·São Paulo Medical Journal = Revista Paulista De Medicina·Camila da Cruz Gouveia LinardiValeria Buccheri
Aug 31, 2007·European Journal of Haematology. Supplementum·Gunnar Birgegård
May 27, 2009·Hematological Oncology·Gunnar Birgegård
Feb 15, 2013·Experimental and Therapeutic Medicine·Lian GuNong Tang
Jan 1, 1997·Hematology·T C Pearson, T Barbui

❮ Previous
Next ❯

Related Concepts

Related Feeds

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.